Get the Stockscreener App
166.55
16.08%
-31.91
After Hours:
166.78
0.23
+0.14%
Insmed Inc stock is traded at $166.55, with a volume of 13.45M.
It is down -16.08% in the last 24 hours and down -17.39% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$198.46
Open:
$167.75
24h Volume:
13.45M
Relative Volume:
5.15
Market Cap:
$35.52B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-26.94
EPS:
-6.1812
Net Cash Flow:
$-906.14M
1W Performance:
-14.69%
1M Performance:
-17.39%
6M Performance:
+67.45%
1Y Performance:
+137.93%
1-Day Range:
$161.02
$172.31
1-Week Range:
$161.02
$205.23
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Biotech, Up 181%, Faces Its 'Worst-Case Scenario' And Dives - Investor's Business Daily
Will Insmed Incorporated stock remain a Wall Street favoriteJuly 2025 Earnings & Step-by-Step Swing Trade Plans - Улправда
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts - ts2.tech
Medical Stocks Worth WatchingDecember 18th - MarketBeat
Micron, Insmed among market cap stock movers on Thursday - Investing.com
INSM: TD Cowen Adjusts Insmed's Price Target Amid Buy Rating | I - GuruFocus
Is Insmed’s 183.7% 2025 Surge Justified by Its Long Term Growth Outlook? - simplywall.st
INSM: Goldman Sachs Lowers Price Target to $225, Maintains Buy R - GuruFocus
Insmed (NASDAQ:INSM) Given New $241.00 Price Target at TD Cowen - MarketBeat
Insmed (INSM) Stock Drops Significantly Amid Market Fluctuations - GuruFocus
INSM: HC Wainwright & Co. Adjusts Price Target, Maintains Buy Ra - GuruFocus
Why Is Insmed Stock Falling Thursday? - Benzinga
Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says - marketscreener.com
After year of triumph, Insmed stumbles with chronic rhinosinusitis fail, brings in new asset - Endpoints News
High-flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri - Fierce Pharma
Stock Traders Buy Large Volume of Call Options on Insmed (NASDAQ:INSM) - MarketBeat
Insmed (INSM) Stock Drops Over 18% Amid Market Volatility - GuruFocus
Insmed (NASDAQ:INSM) Shares Gap Down on Analyst Downgrade - MarketBeat
Cracking its growth story, Insmed’s nasal inflammation study fails - statnews.com
Insmed stock price target lowered to $241 at TD Cowen on missed trial - Investing.com
Mizuho Adjusts Price Target on Insmed to $212 From $256, Maintains Outperform Rating - marketscreener.com
INSM Stock Target Price Lowered by RBC Capital Amid Positive Rat - GuruFocus
Insmed stock price target lowered to $212 by Mizuho after negative study data - Investing.com India
Insmed stock rating reiterated at Buy by Stifel despite trial failure - Investing.com Canada
Guggenheim Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
Insmed adds to pipeline amid brensocatib failure - The Pharma Letter
Insmed’s Brensocatib Hits The Buffers In Sinusitis - Citeline News & Insights
How Insmed Incorporated (IM8N) stock correlates with oil markets2025 Historical Comparison & Risk Managed Investment Entry Signals - Улправда
Insmed stock price target lowered to $195 at RBC Capital on failed study - Investing.com Canada
Cantor Fitzgerald maintains Insmed stock rating despite CRSsNP setback - Investing.com India
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
RBC Lowers Price Target on Insmed to $195 From $215, Keeps Outperform Rating - marketscreener.com
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset - TradingView — Track All Markets
Cantor Fitzgerald maintains Insmed stock rating despite CRSsNP setback By Investing.com - Investing.com UK
Insmed stock plummets 19%. This is what sparked the selloff. - MSN
S&P 500 Futures Rise in Premarket Trading; Insmed, Birkenstock Holding Lag - Barron's
Insmed Stock Plummets 19%. This Is What Sparked the Selloff. - Barron's
Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga
Insmed stock price target lowered to $195 at Leerink on failed trial - Investing.com Canada
Insmed stock falls as Wolfe Research cuts price target on CRSsNP failure - Investing.com Canada
Insmed (INSM) PT Lowered to $203 at BofA Securities - StreetInsider
Micron, Sandisk, DJT, Lululemon, Insmed, Coinbase, Rivian, CarMax, and More Movers - Barron's
Insmed’s ‘win streak’ ends as top drug fails study in chronic nasal condition - Yahoo Finance
Insmed Plunges As Phase 2b BiRCh Data Disappoint; Acquires Phase 2 Ready Monoclonal Antibody - Nasdaq
Insmed sinks after brensocatib fails trial for sinus condition - MSN
The 'worst-case scenario' — why Insmed just reversed its 181% six-month sprint - MSN
Stocks to Watch : Micron, MillerKnoll, HireQuest, Insmed - marketscreener.com
Insmed stock plunges nearly 20% after hours as sinus drug fails mid-stage trial and shows no benefit - MSN
Insmed (INSM) Faces Setback as Brensocatib Trial Falls Short - GuruFocus
Insmed (INSM) Halts Brensocatib Development After Study Misses E - GuruFocus
Insmed (INSM) Expands Portfolio with Acquisition of Promising An - GuruFocus
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):